Document:

Exhibit
4.1

 

THIS
WARRANT AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE
OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR, SUBJECT TO SECTION 11 HEREOF, AN OPINION OF COUNSEL (WHICH MAY BE COMPANY
COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE
SECURITIES LAWS.

 

WARRANT
AGREEMENT

 

To
Purchase Common Shares of

 

VBI
VACCINES, INC.

 

Dated
as of April 24, 2020 (the “Effective Date”)

 

WHEREAS,
VBI Vaccines, Inc., a British Columbia corporation (the “Company”), has entered into a Financial Advisory Services
Agreement of even date herewith (as amended and in effect from time to time, the “Advisory Agreement”) with
National Securities Corporation (“National”);

 

WHEREAS,
pursuant to the Advisory Agreement, the Company has agreed to issue to National, or its designees (the “Warrantholder”)
this Warrant Agreement, evidencing the right to purchase Common Shares of the Company (this “Warrant”, “Warrant
Agreement”, or this “Agreement”);

 

NOW,
THEREFORE, in consideration of National having executed and delivered the Advisory Agreement and provided the financial advisory
services contemplated therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder
agree as follows:

 

SECTION
1. GRANT OF THE RIGHT TO PURCHASE COMMON SHARES.

 

(a)
For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject
to the conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to the number of fully paid and non-assessable
Common Shares (as defined below) as determined pursuant to Section 1(b) below, at a purchase price per share equal to the Exercise
Price (as defined below). The number and Exercise Price of such shares are subject to adjustment as provided in Section 8. As
used herein, the following terms shall have the following meanings:

 

“Act”
means the Securities Act of 1933, as amended.

 

“Charter”
means the Company’s Articles or other constitutional document, as may be amended and in effect from time to time.

 

“Common
Shares” means the Company’s common shares, no par value per share, as presently constituted under the Charter,
and any class and/or series of Company capital stock for or into which such common shares may be converted or exchanged in a reorganization,
recapitalization or similar transaction.

 

    	 

     

    

 

“Exercise
Price” means (i) with respect to the Initial Shares (as defined below), $1.50, subject to adjustment from time to time
in accordance with the provisions of this Warrant.

 

“Liquid
Sale” means the closing of a Merger Event in which the consideration received by the Company and/or its stockholders,
as applicable, consists solely of cash and/or Marketable Securities.

 

“Marketable
Securities” in connection with a Merger Event means securities meeting all of the following requirements: (i) the issuer
thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and is then current in its filing of all required reports and other information
under the Act and the Exchange Act, or subject to the reporting requirements of the Canadian securities laws and is then current
in its filing of all required and other information under such Canadian securities laws; (ii) the class and series of shares or
other security of the issuer that would be received by the Warrantholder in connection with the Merger Event were the Warrantholder
to exercise this Warrant on or prior to the closing thereof is then traded on a Canadian or U.S. national securities exchange
or over-the-counter market, and (iii) following the closing of such Merger Event, Warrantholder would not be restricted from publicly
re-selling all of the issuer’s shares and/or other securities that would be received by Warrantholder in such Merger Event
were Warrantholder to exercise this Warrant in full on or prior to the closing of such Merger Event, except to the extent that
any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond
six (6) months from the closing of such Merger Event.

 

“Merger
Event” means any of the following: (i) a sale, lease or other transfer of all or substantially all assets of the Company,
(ii) any merger or consolidation involving the Company in which the Company is not the surviving entity or in which the outstanding
shares of the Company’s capital stock are otherwise converted into or exchanged for shares of capital stock or other securities
or property of another entity, or (iii) any sale by holders of the outstanding voting equity securities of the Company in a single
transaction or series of related transactions of shares constituting a majority of the outstanding combined voting power of the
Company.

 

“Purchase
Price” means, with respect to any exercise of this Warrant, an amount equal to the then-effective Exercise Price multiplied
by the number of Common Shares as to which this Warrant is then exercised.

 

(b)
Number of Shares. This Warrant shall be exercisable for _______ [705,000] Common Shares, subject to adjustment from
time to time in accordance with the provisions of this Warrant (the “Warrant Shares”).

 

SECTION
2. TERM OF THE AGREEMENT.

 

The
term of this Agreement and the right to purchase Common Shares as granted herein shall commence on the Effective Date and, subject
to Section 8(a) below, shall be exercisable for a period ending upon the third (3rd) anniversary of the Effective Date.

 

    	2

     

    

 

SECTION
3. EXERCISE OF THE PURCHASE RIGHTS.

 

(a)
Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at
any time, or from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its
principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”),
duly completed and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance
with the terms set forth below, and in no event later than two (2) business days thereafter, the Company or its transfer agent
shall, at the direction of the Warrantholder, either (i) issue to the Warrantholder a certificate for the number of Common Shares
purchased, or (ii) credit the same to the Warrantholder no later than the second (2nd) trading day following the Company’s
receipt of the Notice of Exercise, and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit
II (the “Acknowledgment of Exercise”) indicating the number of shares which remain subject to future purchases
under this Warrant, if any.

 

The
Purchase Price may be paid at the Warrantholder’s election either (i) by cash or check, or (ii), if at the time of exercise
hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the
issuance of the Warrant Shares to the Warrantholder, by surrender of all or a portion of the Warrant for Common Shares to be exercised
under this Agreement and, if applicable, an amended Agreement setting forth the remaining number of shares purchasable hereunder,
as determined below (“Net Issuance”). If the Warrantholder elects the Net Issuance method, and such an exercise
is permitted hereunder, the Company will issue Common Shares in accordance with the following formula:

 

	 	 	X
    = Y(A-B)
	 	 	A
	 	 	 
	Where:	X
    =	the
    number of Common Shares to be issued to the Warrantholder.
	 	 	 
	 	Y
    =	the
    number of Common Shares requested to be exercised under this Agreement.
	 	 	 
	 	A
    =	the
    then-current fair market value of one (1) Common Share at the time of exercise.
	 	 	 
	 	B
    =	the
    then-effective Exercise Price.

 

For
purposes of the above calculation, the current fair market value of Common Shares shall mean with respect to each Common Share:

 

(i)
at all times when the Common Shares shall be traded on a national securities exchange, inter-dealer quotation system or over-the-counter
bulletin board service, the volume weighted average price of the Common Shares on the trading day immediately preceding the date
on which Warrantholder elects to exercise this Warrant by means of a Net Issuance, as set forth in the applicable Notice of Exercise;

 

(ii)
if the exercise is in connection with a Merger Event, the fair market value of a Common Share shall be deemed to be the per share
value received by the holders of the outstanding Common Shares pursuant to such Merger Event as determined in accordance with
the definitive transaction documents executed among the parties in connection therewith; or

 

    	3

     

    

 

(iii)
in cases other than as described in the foregoing clauses (i) and (ii), the current fair market value of a Common Share shall
be determined in good faith by the Company’s Board of Directors.

 

Upon
partial exercise by either cash or, upon request by the Warrantholder and surrender of all or a portion of this Warrant, Net Issuance,
prior to the expiration or earlier termination hereof, the Company shall promptly issue an amended Agreement representing the
remaining number of shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical
to those contained herein, including, but not limited to the Effective Date hereof.

 

(b)
Intentionally Omitted.

 

SECTION
4. RESERVATION OF SHARES.

 

During
the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of Common Shares to
provide for the exercise of the rights to purchase Common Shares as provided for herein.

 

SECTION
5. NO FRACTIONAL SHARES OR SCRIP.

 

No
fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of
such fractional shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect.

 

SECTION
6. NO RIGHTS AS STOCKHOLDER.

 

Without
limitation of any provision hereof, Warrantholder agrees that this Agreement does not entitle the Warrantholder to any voting
rights or other rights as a stockholder of the Company prior to the exercise of any of the purchase rights set forth in this Agreement.

 

SECTION
7. WARRANTHOLDER REGISTRY.

 

The
Company shall maintain a registry showing the name and address of the registered holder of this Agreement. Warrantholder’s
initial address, for purposes of such registry, is set forth in Section 12(g) below. Warrantholder may change such address by
giving written notice of such changed address to the Company.

 

SECTION
8. ADJUSTMENT RIGHTS.

 

The
Exercise Price and the number of Common Shares purchasable hereunder are subject to adjustment from time to time, as follows:

 

(a)
Merger Event. In connection with a Merger Event that is a Liquid Sale, this Warrant shall, on and after the closing thereof,
automatically and without further action on the part of any party or other person, represent the right to receive the consideration
payable on or in respect of all Common Shares that are issuable hereunder as of immediately prior to the closing of such Merger
Event less the Purchase Price for all such Common Shares (such consideration to include both the consideration payable at the
closing of such Merger Event and all deferred consideration payable thereafter, if any, including, but not limited to, payments
of amounts deposited at such closing into escrow and payments in the nature of earn-outs, milestone payments or other performance-based
payments), and such Merger Event consideration shall be paid to Warrantholder as and when it is paid to the holders of the outstanding
Common Shares. In connection with a Merger Event that is not a Liquid Sale, the Company shall cause the successor or surviving
entity to assume this Warrant and the obligations of the Company hereunder on the closing thereof, and thereafter this Warrant
shall be exercisable for the same number and type of securities or other property as the Warrantholder would have received in
consideration for the Common Shares issuable hereunder had it exercised this Warrant in full as of immediately prior to such closing,
at an aggregate Exercise Price no greater than the aggregate Exercise Price in effect as of immediately prior to such closing,
and subject to further adjustment from time to time in accordance with the provisions of this Warrant. The provisions of this
Section 8(a) shall similarly apply to successive Merger Events.

 

    	4

     

    

 

(b)
Reclassification of Shares. Except for Merger Events subject to Section 8(a), if the Company at any time shall, by combination,
reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which purchase rights
under this Agreement exist into the same or a different number of securities of any other class or classes of securities, this
Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the
result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately
prior to such combination, reclassification, exchange, subdivision or other change. The provisions of this Section 8(b) shall
similarly apply to successive combination, reclassification, exchange, subdivision or other change.

 

(c)
Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its Common Shares, (i) in the
case of a subdivision, the Exercise Price shall be proportionately decreased and the number of shares for which this Warrant is
exercisable shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be proportionately
increased and the number of shares for which this Warrant is exercisable shall be proportionately decreased.

 

(d)
Stock Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall:

 

(i)
pay a dividend with respect to the outstanding Common Shares payable in additional Common Shares, then the Exercise Price shall
be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that
price determined by multiplying the Exercise Price in effect immediately prior to such date of determination by a fraction (A)
the numerator of which shall be the total number of Common Shares outstanding immediately prior to such dividend or distribution,
and (B) the denominator of which shall be the total number of Common Shares outstanding immediately after such dividend or distribution,
and the number of Common Shares for which this Warrant is exercisable shall be proportionately increased; or

 

(ii)
make any other dividend or distribution on or with respect to Common Shares, except any dividend or distribution (A) in cash,
or (B) specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the
Company such that the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such
distribution as though it were the holder of the Common Shares (or other stock for which the Common Shares are convertible) as
of the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution.

 

(e)
Notice of Certain Events. If: (i) the Company shall declare any dividend or distribution upon its outstanding Common Shares,
payable in stock, cash, property or other securities; (ii) the Company shall offer for subscription pro rata to the holders of
its Common Shares any additional shares of capital stock of any class or other rights; (iii) there shall be any Merger Event;
or (iv) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such
event, the Company shall give the Warrantholder notice thereof at the same time and in the same manner as it gives notice thereof
to the holders of outstanding Common Shares.

 

    	5

     

    

 

SECTION
9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.

 

(a)
Reservation of Common Shares. The Company covenants and agrees that all Warrant Shares that may be issued upon the exercise
of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and non-assessable.
The Company further covenants and agrees that the Company will, at all times during the term hereof, have authorized and reserved,
free from preemptive rights, a sufficient number of Common Shares to provide for the exercise of the rights represented by this
Warrant. If at any time during the term hereof the number of authorized but unissued Common Shares shall not be sufficient to
permit exercise of this Warrant in full, the Company will take such corporate action as may, in the opinion of its counsel, be
necessary to increase its authorized but unissued Common Shares to such number of shares as shall be sufficient for such purposes.

 

(b)
Due Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the
Company hereunder, including the issuance to Warrantholder of the right to acquire the Common Shares, have been duly authorized
by all necessary corporate action on the part of the Company. This Agreement: (1) does not violate the Company’s Charter;
(2) does not contravene any law or governmental rule, regulation or order applicable to it; and (3) except as could not reasonably
be expected to have a material adverse effect, does not and will not contravene any provision of, or constitute a default under,
any indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes
a legal, valid and binding agreement of the Company, enforceable in accordance with its terms, except as may be limited by bankruptcy,
insolvency, reorganization, moratorium or similar laws relating to or affecting creditors’ rights generally (including,
without limitation, fraudulent conveyance laws) and by general principles of equity, regardless of whether considered in a proceeding
in equity or at law.

 

(c)
Consents and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action
in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery
and performance by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation
D under the Act and any filing required by applicable state securities law, which filings will be effective by the time required
thereby.

 

(d)
Exempt Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance of
the Warrant Shares upon exercise of this Agreement will constitute a transaction exempt from (i) the registration requirements
of Section 5 of the Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state
securities laws.

 

    	6

     

    

 

SECTION
10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER.

 

This
Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder:

 

(a)
Investment Purpose. This Warrant and the shares issued on exercise hereof will be acquired for investment and not with
a view to the sale or distribution of any part thereof in violation of applicable federal and state securities laws, and the Warrantholder
has no present intention of selling or engaging in any public distribution of the same except pursuant to a registration or exemption.

 

(b)
Private Issue. The Warrantholder understands (i) that the Warrant Shares are not, as of the Effective Date, registered
under the Act or qualified under applicable state securities laws, and (ii) that the Company’s reliance on exemption from
such registration is predicated on the representations set forth in this Section 10.

 

(c)
Financial Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable
of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment.

 

(d)
Accredited Investor. Warrantholder is an “accredited investor” within the meaning of Rule 501 of Regulation
D promulgated under the Act, as presently in effect (“Regulation D”).

 

(e)
No Short Sales. Warrantholder has not at any time on or prior to the Effective Date engaged in any short sales or equivalent
transactions in the Common Shares. Warrantholder agrees that at all times from and after the Effective Date and on or before the
expiration or earlier termination of this Warrant, it shall not engage in any short sales or equivalent transactions in the Common
Shares.

 

SECTION
11. TRANSFERS.

 

Pursuant
to FINRA Rule 5110(g)(1), neither this Agreement nor any Warrant Shares issued upon exercise of this Agreement shall be sold,
transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction
that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following
the date hereof, except the transfer of any security:

 

i.
by operation of law or by reason of reorganization of the Company;

 

ii.
to any FINRA member firm participating in the offering and the officers and partners thereof, if all securities so transferred
remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period;

 

iii.
if the aggregate amount of the securities of the Company held by the placement agent or related persons do not exceed 1% of the
securities being offered;

 

iv.
that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member
manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the
equity in the fund; or

 

v.
the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section
11 for the remainder of the time period.

 

    	7

     

    

 

Subject
to the foregoing restrictions and compliance with applicable federal and state securities laws, this Agreement and all rights
hereunder are transferable, in whole or in part, without charge to the holder hereof (except for transfer taxes) upon surrender
of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees
that this Agreement, when endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall
have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons
dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented
by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of
a notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices
and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the Company
receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. Notwithstanding
anything herein or in any legend to the contrary, the Company shall not require an opinion of counsel in connection with any sale,
assignment or other transfer by Warrantholder of this Warrant (or any portion hereof or any interest herein) or of any Common
Shares issued upon any exercise hereof to an affiliate (as defined in Regulation D) of Warrantholder, provided that such affiliate
is an “accredited investor” as defined in Regulation D.

 

SECTION
12. MISCELLANEOUS.

 

(a)
Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it
had been executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns
of the Company.

 

(b)
Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights
either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default,
and/or an action for specific performance for any default where Warrantholder will not have an adequate remedy at law and where
damages will not be readily ascertainable.

 

(c)
No Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to
avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying
out of all such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the rights
of the Warrantholder against impairment.

 

(d)
Additional Documents. The Company agrees to supply such other documents as the Warrantholder may from time to time reasonably
request.

 

(e)
Attorneys’ Fees. In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating
hereto, the prevailing party shall be entitled to reasonable attorneys’ fees and expenses and all costs of proceedings incurred
in enforcing this Agreement. For the purposes of this Section 12(e), reasonable attorneys’ fees shall include without limitation
fees incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other
activity of any kind in connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations;
and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce
any judgment.

 

(f)
Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal
or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision
shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the
parties underlying the invalid, illegal or unenforceable provision.

 

    	8

     

    

 

(g)
Notices. Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process
or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter
hereof shall be in writing, and shall be deemed to have been validly served, given, delivered, and received upon the earlier of:
(a) personal delivery to the party to be notified, (b) when sent by confirmed telex, electronic transmission or facsimile if sent
during normal business hours of the recipient, if not, then on the next business day, (c) five days after having been sent by
registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized
overnight courier, specifying next day delivery, with written verification of receipt, and shall be addressed to the party to
be notified as follows:

 

If
to Warrantholder, to the address for the Warrantholder that appears in the Company’s Warrant register;

 

If
to the Company:

 

VBI
VACCINES, INC.

Attention:
Chief Financial Officer

222
Third Street, Suite 2241

Cambridge,
Massachusetts 02142

Facsimile: 

Telephone:

 

or
to such other address as each party may designate for itself by like notice.

 

(h)
Entire Agreement; Amendments. This Agreement constitutes the entire agreement and understanding of the parties hereto in
respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters,
negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof. None of the
terms of this Agreement may be amended except by an instrument executed by each of the parties hereto.

 

(i)
Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or
interpretation of this Agreement or any provisions hereof.

 

(j)
Advice of Counsel. Each of the parties represents to each other party hereto that it has discussed (or had an opportunity
to discuss) with its counsel this Agreement and, specifically, the provisions of Sections 12(n), 12(o), 12(p).

 

(k)
No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement.
In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly
by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement.

 

(l)
No Waiver. No omission or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to require
performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any
such right or remedy to which Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to enforce
such provisions thereafter.

 

(m)
Survival. All agreements, representations and warranties contained in this Agreement or in any document delivered pursuant
hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement in accordance
with their terms.

 

(n)
Governing Law. This Agreement has been negotiated and delivered to Warrantholder in the State of New York, and shall be
deemed to have been accepted by Warrantholder in the State of New York. Delivery of Common Shares to Warrantholder by the Company
under this Agreement is due in the State of New York. This Agreement shall be governed by, and construed and enforced in accordance
with, the laws of the State of New York, excluding conflict of laws principles that would cause the application of laws of any
other jurisdiction.

 

    	9

     

    

 

(o)
Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought
in any state or federal court of competent jurisdiction located in the State of New York. By execution and delivery of this Agreement,
each party hereto generally and unconditionally: (a) consents to personal jurisdiction in New York County, State of New York;
(b) waives any objection as to jurisdiction or venue in New York County, State of New York; (c) agrees not to assert any defense
based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered
thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to
this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 12(g), and shall
be deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any
other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

 

(p)
Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most quickly
and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply
(rather than arbitration rules), the parties desire that their disputes arising under or in connection with this Warrant be resolved
by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL
BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”)
ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY RELATING
TO THIS WARRANT. This waiver extends to all such Claims, including Claims that involve persons or entities other the Company and
Warrantholder; Claims that arise out of or are in any way connected to the relationship between the Company and Warrantholder;
and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out
of this Agreement.

 

(q)
Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number
of counterparts (including by facsimile or electronic delivery (PDF), and by different parties hereto in separate counterparts,
each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same
instrument.

 

(r)
Specific Performance. The parties hereto hereby declare that it is impossible to measure in money the damages which will
accrue to Warrantholder by reason of the Company’s failure to perform any of the obligations under this Agreement and agree
that the terms of this Agreement shall be specifically enforceable by Warrantholder. If Warrantholder institutes any action or
proceeding to specifically enforce the provisions hereof, any person against whom such action or proceeding is brought hereby
waives the claim or defense therein that Warrantholder has an adequate remedy at law, and such person shall not offer in any such
action or proceeding the claim or defense that such remedy at law exists.

 

    	10

     

    

 

(s)
Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company may,
on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include
the surrender thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.
Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen,
mutilated or destroyed Warrant shall be at any time enforceable by anyone.

 

(t)
Legends. To the extent required by applicable laws, this Warrant and the Warrant Shares (and the securities issuable, directly
or indirectly, upon conversion of such Warrant Shares, if any) may be imprinted with a restricted securities legend in substantially
the following form:

 

THIS
SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE
SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT
AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT
AND ANY APPLICABLE STATE SECURITIES LAWS.

 

[Remainder
of Page Intentionally Left Blank]

 

    	11

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by its officers thereunto duly authorized
as of the Effective Date.

 

	COMPANY:	VBI
    VACCINES, INC.
	 	 
	 	By:
    	                      
	 	Name:
    	 
	 	Title:
    	 
	 	 	 
	WARRANTHOLDER:	
	 	 	 
	 	By:
    	                     
	 	Name:
    	 
	 	Title:
    	 

 

    	12

     

    

 

EXHIBIT
I

 

NOTICE
OF EXERCISE

 

	To:	[____________________________]
	 	 
	(1)	The
    undersigned Warrantholder hereby elects to purchase [_______] Common Shares of VBI Vaccines, Inc., pursuant to the terms of
    the Agreement dated the [___] day of [______, _____] (the “Agreement”) between VBI Vaccines, Inc. and the Warrantholder,
    and tenders herewith payment of the Purchase Price in full, together with all applicable transfer taxes, if any. [NET ISSUANCE:
    if permitted, elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.]
	 	 
	(2)	Please
    issue a certificate or certificates representing said Common Shares in the name of the undersigned or in such other name as
    is specified below.

 

	 	 
	 	(Name)
	 	            
	 	 
	 	(Address)
	 	 	                                   
	WARRANTHOLDER:	
	 	 	 
	 	By:
    	                     
	 	Name:
    	 
	 	Title:	 

 

    	13

     

    

 

EXHIBIT
II

 

1.
ACKNOWLEDGMENT OF EXERCISE

 

The
undersigned [____________________________________], hereby acknowledge receipt of the “Notice of Exercise” from [___________________]
to purchase [____] Common Shares of VBI Vaccines, Inc., pursuant to the terms of the Agreement, and further acknowledges that
[______] Common Shares remain subject to purchase under the terms of the Agreement.

 

	COMPANY:	VBI
    VACCINES, INC.
	 	 
	 	By:
    	                          
	 	Title:
    	 
	 	Date:
    	 

 

    	14

     

    

 

EXHIBIT
III

 

TRANSFER
NOTICE

 

(To
transfer or assign the foregoing Agreement execute this form and supply required information. Do not use this form to purchase
shares.)

 

FOR
VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby are hereby transferred and assigned to

 

_________________________________________________________________

(Please
Print)

 

whose
address is___________________________________________________

 

_________________________________________________________________

 

Dated:
____________________________________

 

Holder’s
Signature: _______________________________

 

Holder’s
Address: _______________________________

 

Signature
Guaranteed: ____________________________________________

 

NOTE:
The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without alteration
or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity
should file proper evidence of authority to assign the foregoing Agreement.

 

    	15Exhibit 10.1

 

U.S. SMALL BUSINESS
ADMINISTRATION PAYCHECK PROTECTION PROGRAM NOTE

 

	SBA Loan #:	9056777100
	SBA Loan Name:	Paycheck Protection Program Loan
	Loan Date:	4/25/2020
	Loan Amount:	$176,300.00
	Interest Rate:	1.00% fixed
	Borrower:	ARCH THERAPEUTICS, INC
	Lender:	First Republic Bank

 

This Note represents the
Loan (as defined below) made by Lender pursuant to the Paycheck Protection Program (the “PPP”). Borrower confirms
and agrees that the Loan is subject in all respects to the Coronavirus Aid, Relief, and Economic Security Act and the requirements,
rules, regulations, procedures and guidance concerning the PPP in effect as of the date of this Note and as may be promulgated
from time to time after the date of this Note by the U.S. Department of Treasury and/or SBA (collectively, the “PPP Regulations”),
including, without limitation, all PPP Regulations applicable to permitted uses of loan proceeds and loan forgiveness.

 

		1.	PROMISE TO PAY

 

In return for the Loan, Borrower promises to pay to
the order of Lender the amount of $176,300.00

 

Dollars, interest on the unpaid principal balance, and
all other amounts required by this Note.

 

		2.	DEFINITIONS

 

“Loan” means the loan evidenced by
this Note.

 

“Loan Documents”
means the documents related to this Loan signed by Borrower, including the Borrower Application Form for the Paycheck Protection
Program, the Borrower Certificate executed and delivered by Borrower in connection with this Note and all other attestations, certificates,
agreements and documents delivered by Borrower to Lender in connection with the Loan.

 

“SBA” means
the Small Business Administration, an Agency of the United States of America.

 

		3.	PAYMENT TERMS

 

Borrower must make all payments at the place Lender
designates. The payment terms for this Note are:

 

Initial Deferment Period: No payments are
due on this Loan for 6 months from the date of first disbursement of this Loan. Interest will continue to accrue during the deferment
period.

 

     

     

    

 

Loan Forgiveness:
Borrower may apply to Lender for forgiveness of the amount due on this Loan in an amount equal to the sum of the following costs
incurred by Borrower during the 8-week period beginning on the date of first disbursement of this Loan:

 

		a.	Payroll costs

		b.	Any payment of interest on a covered mortgage obligation (which shall not include any prepayment
of or payment of principal on a covered mortgage obligation)

		c.	Any payment on a covered rent obligation

		d.	Any covered utility payment

 

The amount of Loan forgiveness
shall be calculated (and may be reduced) in accordance with the requirements of the PPP, including the provisions of Section 1106
of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) (P.L. 116-136). Not more than 25% of the amount forgiven
can be attributable to non-payroll costs. If Borrower has received an EIDL advance, then that amount shall be subtracted from the
loan forgiveness amount.

 

Maturity: This Note
will mature on the date that is two years from date of first disbursement of this Loan.

 

Repayment
Terms:

 

Interest Rate: The
interest rate on this Note is one percent per year. The interest rate is fixed and will not be changed during the life of the Loan.

 

Installment Payments
Following Deferment Period: Borrower must pay monthly principal and interest payments on the outstanding principal balance
of the Loan amortized over the term of the Loan, unless otherwise forgiven in whole or part in accordance with the PPP Regulations,
beginning 7 months from the date of the first disbursement of this Loan until the maturity date. Payments of principal and interest
must be made on such date as designated by Lender in the months during which they are due. Any Loan balance remaining following
forgiveness pursuant to the PPP Regulations, if any, will be fully reamortized over the remaining term of the Loan.

 

Application of Installment
Payments: Lender will apply each installment payment first to pay interest accrued to the day Lender received the payment,
then to bring principal current, and will apply any remaining balance to reduce principal.

 

Payment at Maturity.
All remaining principal and accrued interest is due and payable two years from the date of first disbursement of this Loan.

 

Loan Prepayment: Notwithstanding
any provision in this Note to the contrary:

 

Borrower may prepay this
Note at any time without penalty. Borrower may prepay 20 percent or less of the unpaid principal balance at any time without
notice. If Borrower prepays more than 20 percent and the Loan has been sold on the secondary market, Borrower must:

 

		a.	Give Lender written notice;

		b.	Pay all accrued interest; and

		c.	If the prepayment is received less than 21 days from the date Lender receives
the notice, pay an amount equal to 21 days interest from the date Lender receives the notice, less any interest accrued during
the 21 days and paid under b. of this paragraph.

 

     

     

    

 

If Borrower does not prepay within 30 days from
the date Lender receives the notice, Borrower must give Lender a new notice.

 

Non-Recourse: Lender
and SBA shall have no recourse against any individual shareholder, member or partner of Borrower for non-payment of the Loan, except
to the extent that such shareholder, member or partner uses the Loan proceeds for an unauthorized purpose.

 

		4.	DEFAULT

 

Borrower is in default under this Note if Borrower
does not make a payment when due under this Note, or if Borrower:

 

		A.	Fails to do anything required by this Note and other
Loan Documents;

 

		B.	Defaults on any other loan with Lender;

 

		C.	Does not disclose, or anyone acting on its behalf
does not disclose, any material fact to Lender or SBA;

 

		D.	Makes, or anyone acting on its behalf makes, (i) a
materially false or misleading representation to Lender or SBA or (ii) a false or incorrect statement or certification in any
certificate, attestation or agreement included in any Loan Documents;

 

		E.	Defaults on any loan or agreement with another creditor,
if Lender believes the default may materially affect Borrower’s ability to pay this Note;

 

		F.	Fails to pay any taxes when due;

 

		G.	Becomes the subject of a proceeding under any bankruptcy
or insolvency law;

 

		H.	Has a receiver or liquidator appointed for any part
of their business or property;

 

		I.	Makes an assignment for the benefit of creditors;

 

		J.	Has any adverse change in financial condition or business
operation that Lender believes may materially affect Borrower’s ability to pay this Note;

 

		K.	Reorganizes, merges, consolidates, or otherwise changes
ownership or business structure without Lender’s prior written consent; or

 

		L.	Becomes the subject of a civil or criminal action
that Lender believes may materially affect Borrower’s ability to pay this Note.

 

		5.	LENDER’S RIGHTS IF THERE IS A DEFAULT

 

Without notice or demand and without giving up any of
its rights, Lender may:

 

		A.	Require immediate payment of all amounts owing under
this Note;

 

		B.	Collect all amounts owing from Borrower; or

 

     

     

    

 

		C.	File suit and obtain judgment.

 

		6.	LENDER’S GENERAL POWERS

 

Without notice and without Borrower’s
consent, Lender may:

 

		A.	Incur expenses to collect amounts due under this Note, enforce the terms
of this Note or any other Loan Document. Among other things, the expenses may include payments for property taxes, prior liens,
insurance, appraisals, environmental remediation costs, and reasonable attorney’s fees and costs. If Lender incurs such expenses,
it may demand immediate repayment from Borrower or add the expenses to the principal balance; and

 

		B.	Release anyone obligated to pay this Note.

 

		7.	WHEN FEDERAL LAW APPLIES; GOVERNING LAW AND VENUE

 

When SBA is the holder, this
Note will be interpreted and enforced under federal law, including SBA regulations. As to this Note, Borrower may not claim or
assert against SBA any local or state law to deny any obligation, defeat any claim of SBA, or preempt federal law.

 

When the SBA is not the holder,
this Note will be interpreted and enforced under the laws of the State of California. All judicial proceedings arising in or under
or related to the Loan, this Note or any of the other Loan Documents may be brought in any state or federal court located in a
state where Lender has an office (each, a “Lender’s State”). By execution and delivery of this Note, Borrower
generally and unconditionally:

(a) consents to nonexclusive
personal jurisdiction in each Lender’s State; (b) waives any objection as to jurisdiction or venue in each Lender’s
State; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably
agrees to be bound by any judgment rendered thereby in connection with the Loan, this Loan or the other Loan Documents.

 

		8.	SUCCESSORS AND ASSIGNS

 

Under this Note, Borrower includes
its successors, and Lender includes its successors and assigns.

 

Lender may at any time assign
to one or more assignees all or a portion of its rights and obligations under this Note.

 

		9.	OTHER AGREEMENTS AND GENERAL PROVISIONS

 

		A.	Borrower understands and agrees, and waives and releases Lender, as follows:

 

		a.	Forgiveness of the Loan is only available for principal
that is used for the limited purposes that qualify for forgiveness under the PPP Regulations, and that to obtain forgiveness,
Borrower must request it and must provide documentation in accordance with the PPP Regulations, and certify that the amounts Borrower
is requesting to be forgiven qualify under the PPP Regulations. Borrower also understands that Borrower shall remain responsible
under the Loan for any amounts not forgiven, and that interest payable under the Loan will not be forgiven but that the SBA may
pay the Loan interest on forgiven amounts.

 

		b.	Forgiveness is not automatic and Borrower must request
it. Borrower is not relying on Lender for its understanding of the requirements for forgiveness such as eligible expenditures, necessary records/documentation,
or possible reductions due to changes in number of employees or compensation. Rather Borrower will consult the PPP Regulations
and SBA’s program materials.

 

     

     

    

  

		B.	All individuals and entities signing this Note are
jointly and severally liable.

 

		C.	Borrower waives all suretyship defenses.

 

		D.	Borrower must sign all documents necessary at any
time to comply with the Loan Documents.

 

		E.	Lender may exercise any of its rights separately or
together, as many times and in any order it chooses. Lender may delay or forgo enforcing any of its rights without giving up any
of them.

 

		F.	Borrower may not use an oral statement of Lender or
SBA to contradict or alter the written terms of this Note.

 

		G.	If any part of this Note is unenforceable, all other
parts remain in effect.

 

		H.	To the extent allowed by law, Borrower waives all
demands and notices in connection with this Note, including presentment, demand, protest, and notice of dishonor. Borrower also
waives any defenses based upon any claim that Lender did not obtain any guarantee.

 

		10.	FURTHER ASSURANCES

 

The Loan and this Note are
subject in all respects to the PPP Regulations, including any PPP Regulations promulgated after the date of this Note. If after
the date of this Note, any further PPP Regulations are promulgated or if the PPP Regulations mandate a form of or the terms of
the note, loan authorization or other loan documents for PPP loans, Borrower agrees to execute any further instruments and documents
and to take such further actions as Lender requests, including exchanging this Note for new note, executing an amendment to this
Note, or executing any other loan documents that Lender requests. In the event of any exchange of or amendment to this Note, the
disbursement date applicable to the Loan (and all related time periods under the PPP Regulations and the maturity date applicable
to this Loan) shall be the same as set forth in this Note.

 

		11.	BORROWER’S NAME AND SIGNATURE

 

By signing below, each individual or entity executing
this Note as “Borrower” becomes obligated under this Note as Borrower.

 

BORROWER:

 

	ARCH THERAPEUTICS, INC	 
	 	 	 
	By:	/s/ Richard E Davis	 
	 	RICHARD E DAVIS	 
	 	CHIEF FINANCIAL OFFICER	 
	 	 	 
	 	4/25/2020	 
	 	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]